Biotech Drug Report Generated Jul 2, 2026

TN-201

TNYA·Tenaya Therapeutics, Inc.

MIXED

Drug Impact Rating4/10

Trial Phase: Phase 1b/2
Time to Market: Unlikely before 2028-2029; still in Phase 1b/2, with pivotal study design not yet aligned with regulators
Why 4/10: No PDUFA or pivotal Phase 3 readout is scheduled within the next ~12 months. TN-201 remains in Phase 1b/2 (MyPEAK-1). The next catalysts are additional long-term follow-up data and regulatory-alignment updates expected in H2 2026 — informative but not hard binary events. TN-201 is Tenaya's lead asset but the company also has a second gene therapy (TN-401) in the clinic, so it is not a pure single-asset binary. ImpactScore: 4.

Actionable Insight MIXED

TN-201 is an early-stage (Phase 1b/2) gene therapy showing encouraging signs of cardiac remodeling and symptom improvement in a small number of patients. The stock trades near ~$0.79 with a mean analyst price target of $4.00 (400% implied upside), reflecting optimism around the gene therapy approach. However, the company carries significant risk: small patient numbers (n=6 dosed across two cohorts), a history of FDA clinical hold (since resolved), and an $80.9M cash balance that must fund operations into H2 2027. Watch for regulatory alignment updates in H2 2026, which could clarify the pivotal trial pathway and serve as a meaningful derisking event.

Price Chart

Loading chart...

Executive Summary

TN-201 is Tenaya Therapeutics' lead asset — a one-time AAV9 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), the most common genetic form of the disease. Interim data from the Phase 1b/2 MyPEAK-1 trial have shown encouraging and durable signs of cardiac remodeling (reduced left ventricular wall thickness, improved mass index), biomarker improvements, and symptom reduction in all evaluable patients, with benefits sustained out to two years in the low-dose cohort. The drug has received FDA Fast Track, Orphan Drug, and Rare Pediatric Drug Designations, plus EMA PRIME designation. However, the dataset is very small (n=6 total dosed), the company has a history of a clinical hold (now resolved), and Tenaya has ~$80.9M in cash funding operations into H2 2027. No approved therapy currently addresses the genetic cause of MYBPC3-HCM, positioning TN-201 as a potential first-in-class disease-modifying treatment if it succeeds in larger trials.

How It Works

TN-201 is a one-time gene therapy that delivers a working copy of the MYBPC3 gene into heart muscle cells using a harmless, modified virus shell (AAV9). MYBPC3 mutations are the most common genetic cause of hypertrophic cardiomyopathy (HCM) — a disease where the heart muscle becomes abnormally thick, making it harder to pump blood. The therapy is designed to restore production of a key structural protein (MyBP-C) in heart cells, potentially halting or reversing the disease at its genetic root cause.

Trial Status

MyPEAK-1 Phase 1b/2 open-label trial (NCT05836259) is actively enrolling and dosing. Two dose cohorts (3E13 vg/kg and 6E13 vg/kg) have reported interim data. Cohort 1 patients (n=3, low dose) have 78-104 weeks of follow-up showing sustained benefits. Cohort 2 patients (n=3, high dose) have 26-52 weeks of follow-up with early signs of dose-responsive protein expression. The FDA had placed a clinical hold in Sept 2025 (brief safety review), which was lifted by Dec 2025. Tenaya plans to pursue regulatory alignment on pivotal studies in H2 2026.

The Two-Sided Case

▲ Bull Case5

First-in-class gene therapy targeting the most common genetic cause of HCM (~20% of all HCM patients, ~120,000 patients in the U.S.) with no approved therapy addressing the underlying genetic cause — potentially a blockbuster opportunity if successful.

Interim Phase 1b/2 data are encouraging: all evaluable patients showed improvements in multiple HCM hallmarks, with low-dose Cohort 1 patients sustaining benefits out to 2 years — including reductions in left ventricular posterior wall thickness (up to 40% into normal range) and biomarker normalization (cardiac troponin I declined 48-74%).

Rich regulatory tailwind: FDA Fast Track, Orphan Drug, and Rare Pediatric Drug Designations, plus EMA PRIME and Orphan Medicinal Product designations — all of which can accelerate development, provide market exclusivity, and reduce regulatory risk.

Strong institutional accumulation: Renaissance Technologies doubled its position (+100.6% in Q1 2026), Marshall Wace added significantly (+92.4%), and Vanguard and BlackRock each added ~69% in Q4 2025. Analyst consensus is heavily bullish: 9 Buy, 1 Hold, 0 Sell; mean price target $4.00 vs ~$0.79 current price (~400% implied upside).

Cash runway into H2 2027 ($80.9M plus $10M Alnylam upfront) and a second pipeline program (TN-401 for PKP2-ARVC) diversifies the story beyond just TN-201.

▼ Bear Case5

Extremely early-stage with tiny dataset: only 6 patients total have been dosed across two cohorts. Efficacy signals come from an open-label, non-randomized study with no placebo control — subject to selection bias and confounding.

History of FDA clinical hold (Sept-Dec 2025) after a safety signal (complement elevation from innate immune response). While resolved, this highlights the safety risks inherent to high-dose AAV gene therapy, which may recur in larger patient populations.

HCM is a crowded competitive space with approved therapies: BMS's Camzyos (mavacamten) is approved for obstructive HCM and generating billions, and Cytokinetics' aficamten is in late-stage development. TN-201 targets a specific genetic subset (MYBPC3-mutant nonobstructive HCM), which limits peak market size.

Significant dilution risk: with a ~$0.79 stock price and only $80.9M in cash, Tenaya will almost certainly need to raise capital again to fund pivotal trials, which are likely years away. The current market cap is already signal-constrained by the tiny data set.

Gene therapy has a mixed track record in cardiology — no cardiac gene therapy has ever been approved. Durability of expression, immune response management, and manufacturability at scale remain unproven for this indication.

Upcoming Catalysts

H2 2026: Additional long-term follow-up data (1-year Cohort 2, 2-year Cohort 1) from MyPEAK-1 trial.
H2 2026: Regulatory alignment update on TN-201 pivotal study design and endpoints — a key de-risking event that could shape the path to registration.
Ongoing: Enrollment and dosing updates for the MyPEAK-1 trial (potential for additional dose cohorts or expansion).
Q3 2026: Potential presentation of updated data at cardiology or gene therapy conferences.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Tenaya Therapeutics, Inc. 8-K TNYA ·Originating report

Sources · 15

Hover a chip for the title

1 tenayatherapeutics.com2 markets.businessinsider.com3 globenewswire.com4 investors.tenayatherapeutics.com5 investors.tenayatherapeutics.com6 investors.tenayatherapeutics.com7 clinicaltrialvanguard.com8 packgene.com9 investors.tenayatherapeutics.com10 academic.oup.com11 stocktitan.net12 sahmcapital.com13 morningstar.com14 delveinsight.com15 seekingalpha.com